Streetwise Biotech/Pharmaceuticals Articles



RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report  (2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >


0

Investing in Life Sciences Under the Trump Presidency
Source: Kristin McFarland for The Life Sciences Report  (2/16/17)
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. More >


Regeneus Hits the Fast Track with Major Japanese Partnership
Source: The Life Sciences Report  (2/8/17)
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. More >


The Future of Cannabis Investing
Source: Tom Beck for Streetwise Reports  (2/3/17)
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global. More >


ContraVir's Hep B Drug Could Be a Game Changer
Source: The Life Sciences Report  (2/1/17)
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company. More >


Colin Lee Novick

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report  (2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >


Inovio's Zika Vaccine Generates Robust Immune Responses
Source: The Life Sciences Report  (1/25/17)
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. More >


2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Source: The Life Sciences Report  (1/18/17)
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. More >


Jason Napodano

Time to Go Long on BrainStorm Cell Therapeutics?
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report  (1/16/17)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. More >


19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Source: The Life Sciences Report  (1/3/17)
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. More >


VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
Source: The Life Sciences Report  (12/21/16)
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. More >


Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth
Source: The Life Sciences Report  (12/14/16)
3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements.
More >


Reliq Health Technologies Pilots Remote Patient Monitoring Program
Source: The Life Sciences Report  (12/7/16)
Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology. More >


Can Biotech's Trump Bump Last?
Source: The Life Sciences Report  (12/2/16)
In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. More >


Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena
Source: The Life Sciences Report  (11/14/16)
By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future. More >


Len Yaffe

Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
Source: Dr. Len Yaffe for The Life Sciences Report  (11/2/16)
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation policy, and focuses in on one California ballot proposition that aims to rein in costs. More >


Analysts Keep Focus on DURECT's DUR-928
Source: The Life Sciences Report  (10/6/16)
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma. More >


Regeneus Secures Government Funding for R&D
Source: The Life Sciences Report  (9/14/16)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. More >


Three Shots on Goal in Q4/16 for DURECT Corp.
Source: The Life Sciences Report  (9/8/16)
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. More >


Soligenix's Diversified Pipeline Advances on All Fronts
Source: The Life Sciences Report  (8/31/16)
The late-stage biopharmaceutical company Soligenix has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape. More >


Inovio Expands Ebola Vaccine Trial
Source: The Life Sciences Report  (8/24/16)
Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination. More >


Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Source: The Life Sciences Report  (8/17/16)
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. More >


Stuart Roberts

The ASX: Investing in an Emerging Biotech Frontier
Source: Stuart Roberts for The Life Sciences Report  (8/10/16)
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. More >


Resverlogix Seeks Orphan Status for Lead Drug Candidate
Source: The Life Sciences Report  (8/3/16)
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications. More >


DURECT's Abuse-Deterrent Opioid Poised for FDA Approval
Source: Tracy Salcedo of The Life Sciences Report  (7/13/16)
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative. More >


Showing Results: 1 to 25 of 305 Next